...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats
【24h】

Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats

机译:聚酰胺酰胺树状聚合物作为新型的潜在吸收促进剂,可改善大鼠难吸收药物的小肠吸收

获取原文
获取原文并翻译 | 示例
           

摘要

Effects of polyamidoamine (PAMAM) dendrimers on the intestinal absorption of poorly absorbable drugs were examined by an in situ closed loop method in rats. 5(6)-Carboxyfluorescein (CF), fluorescein isothiocyanate-dextrans (FDs) with various molecular weights, calcitonin and insulin were used as model drugs of poorly absorbable drugs. The absorption of CF, FD4 and calcitonin from the rat small intestine was significantly enhanced in the presence of PAMAM dendrimers. The absorption-enhancing effects of PAMAM dendrimers for improving the small intestinal absorption of CF were concentration and generation dependent and a maximal absorption-enhancing effect was observed in the presence of 0.5% (w/v) G2 PAMAM dendrimer. However, G2 PAMAM dendrimer had almost no absorption-enhancing effect on the small intestinal absorption of macromolecular drugs including FD10 and insulin. Overall, the absorption-enhancing effects of G2 PAMAM dendrimer in the small intestine decreased as the molecular weights of drug increased. However, G2 PAMAM dendrimer did not enhance the intestinal absorption of these drugs with different molecular weights in the large intestine. Furthermore, we evaluated the intestinal membrane damage with or without G2 PAMAM dendrimer. G2 PAMAM dendrimer (0.5% (w/v)) significantly increased the activities of lactate dehydrogenase (LDH) and the amounts of protein released from the intestinal membranes, but the activities and amounts of these toxic markers were less than those in the presence of 3% Triton X-100 used as a positive control. Moreover, G2 PAMAM dendrimer at concentrations of 0.05% (w/v) and 0.1% (w/v) did not increase the activities and amounts of these toxic markers. These findings suggested that PAMAM dendrimers at lower concentrations might be potential and safe absorption enhancers for improving absorption of poorly absorbable drugs from the small intestine.
机译:通过原位闭环法在大鼠中检查了聚酰胺型胺(PAMAM)树状聚合物对难吸收药物的肠道吸收的影响。 5(6)-羧基荧光素(CF),分子量不同的荧光素异硫氰酸酯-右旋糖酐(FDs),降钙素和胰岛素被用作难吸收药物的模型药物。在存在PAMAM树状聚合物的情况下,大鼠小肠对CF,FD4和降钙素的吸收显着增强。 PAMAM树枝状大分子改善CF的小肠吸收的吸收增强作用与浓度和世代有关,在存在0.5%(w / v)G2 PAMAM树枝状大分子的情况下,观察到最大的吸收增强作用。但是,G2 PAMAM树状聚合物对包括FD10和胰岛素的大分子药物的小肠吸收几乎没有吸收增强作用。总体而言,随着药物分子量的增加,G2 PAMAM树状聚合物在小肠中的吸收增强作用降低。但是,G2 PAMAM树枝状大分子并没有增强这些分子量不同的药物在大肠中的肠道吸收。此外,我们评估了有或没有G2 PAMAM树状聚合物的肠膜损伤。 G2 PAMAM树状聚合物(0.5%(w / v))显着增加了乳酸脱氢酶(LDH)的活性和从肠膜释放的蛋白质的量,但这些毒性标志物的活性和量均低于存在DHA的情况。 3%的Triton X-100用作阳性对照。此外,浓度为0.05%(w / v)和0.1%(w / v)的G2 PAMAM树状聚合物不会增加这些毒性标志物的活性和含量。这些发现表明,较低浓度的PAMAM树状聚合物可能是潜在的和安全的吸收促进剂,可改善小肠对难吸收药物的吸收。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号